** Shares of medical device maker Insulet PODD.O rise 8.8% to $268 premarket

** Co reports Q4 adjusted EPS of $1.55, above analysts' estimates of $1.45 - data compiled by LSEG

** Posts Q4 sales of $783.8 million, above estimates of $768.7 million

** Co expects 2026 revenue growth of 20% to 22% in constant currency, with adjusted earnings per share expected to climb more than 25%

** For Q1, co forecast 25% to 27% revenue growth in constant currency

** "We believe the FY26 guide will be viewed positively by investors, supported by strong underlying growth both in the US and OUS," said Leerink Partners analyst Mike Kratky

** In 2025, PODD gained 10.7%

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))